A scientific research lab advancing knowledge through discovery.

Cambridge GenetiX is introducing Cutting edge CAR-T Cell Therapy (Ariflex) for treatment of Acute Lymphoblastic leukemia (ALL) and Diffused Large B Cell Lymphoma (DLBCL)

GX-01 is fully Humanized anti ScFV Fragment with 2nd Generation of Chimeric Antigen receptor providing unmatchable safety and efficacy in patients.

About Us

From a Nobel Laureate’s Lab, Committed to Impact in Developed and Developing Worlds

Cambridge GenetiX was founded in Cambridge United Kingdom with a mission to redefine the development and delivery of advanced biologics, cell therapies, and gene therapies. Built on scientific foundations shaped in the laboratory of a Nobel Prize winning scientist and a legacy of creating transformative biotechnology companies, we are committed to delivering innovation and quality to patients worldwide. Located at the Cambridge Biomedical Campus alongside global leaders such as AstraZeneca, we operate within one of the world’s most dynamic life sciences ecosystems. By integrating cutting edge engineering, advanced manufacturing, and deep scientific expertise, Cambridge GenetiX develops accessible, scalable, and clinically meaningful therapies that bridge breakthrough science with real world patient needs.

Our Science

Our science: smarter antibodies for safer, longerlasting CART

Most current CART therapies use an antibody fragment that was originally made in mice. That “murine” design helps the CART cell find the cancer, but the mousederived part can look foreign to the human immune system. Over time, the body can start to recognize it as an intruder, which may trigger strong cytokine release, unwanted immune reactions, and can make it harder or riskier to give repeat treatments.

Our Ariflex (GX1) antibody was engineered to solve that problem. It is a fully humanized antibody, carefully redesigned so that it still locks onto the cancer target, but now looks and behaves much more like a natural human antibody. That humanlike design is expected to reduce serious immune side effects and lower the chance that the patient’s immune system will attack the CART cells themselves. In simple terms: we keep the precision of a smart weapon, while removing the “mouse” parts that make it more likely to cause trouble.

By building CART therapies on top of Ariflex (GX1), we aim to deliver powerful antitumor activity with a cleaner immunogenicity profile and a better safety margin. This gives clinicians more room to treat, retreat, and combine therapies, and gives patients a better chance at durable benefit with fewer serious immune complications.

Clinical Grade Reagents (GMP)

CART Per Patient Kit

Build highquality CART cells for every patient, from a single box. Our CART Per Patient Kit combines all critical reagents and protocols needed to engineer, expand, and prepare CART cells for one individual. Standardized components and stepbystep workflows help reduce variability between runs, support GMP alignment, and shorten handson time for your team—so you can focus on patients, not chasing reagents.

CART Extensive Validation Antibody Panel

Derisk your product release with deep Tcell profiling. This readytouse antibody panel is designed to characterize CART phenotype, activation, memory, and exhaustion status in a single flow cytometry run. It enables rigorous inprocess and finalproduct quality control, helping you document that each batch meets predefined identity, purity, and functional criteria before it reaches the clinic.

CAR Detection Reagent

See your CAR, quantify your product. Our highly specific CAR Detection Reagent binds directly to the CAR on engineered cells, enabling sensitive, reproducible measurement of CAR expression by flow cytometry. Use it to optimize transduction conditions, monitor manufacturing consistency, and support release testing with clear, quantitative data on the percentage and intensity of CARpositive T cells.

InterferonGamma Detection Kits

Functional readouts that go beyond phenotype. These ELISA/ELISpotbased InterferonGamma Detection Kits provide a robust measure of CART cell potency in response to target engagement. By quantifying IFNγ secretion, you can link phenotype to function, compare manufacturing conditions, and document a critical aspect of immune activity during validation and lot release.

Scale Your Breakthrough With Us

Bridging the gap between discovery and the clinic.

Partner with Cambridge GenetiX to leverage our Nobel-prize-winning foundations and GMP-grade expertise. Let’s accelerate the next generation of life-changing therapies together.